Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts. (27th July 2021)

• Record Type: Journal Article
• Authors: Monroe, Anne K; Levy, Matthew E; Greenberg, Alan E; Keruly, Jeanne C; Moore, Richard D; Horberg, Michael A; Kulie, Paige; Mohanraj, Bernadine S; Kumar, Princy N; Castel, Amanda D
• Is Part Of: Open forum infectious diseases. Volume 8:Number 8(2021)
• Publication Date: 2021-07-27
• Subjects: cohort -- disparities -- HIV -- integrase strand transfer inhibitors (INSTIs) -- transgender; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab338
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons. Abstract : We assessed INSTI prescribing disparities using Johns Hopkins HIV Clinical Cohort/DC Cohort data. Disparities were noted, including clinic location, age, and being transgender. Clinicians should focus their attention on these individuals and make therapy decisions grounded in valid clinical reasons.